A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
In the register
The register attaches this trial to Ruxolitinib cream (alopecia areata) (Incyte), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Terminated early
- Declared phase
- Phase 2
- Sponsor
- Incyte Corporation
- Participants (registry)
- 90
- Start
- November 2015
- Primary completion
- October 2017
- Study completion
- October 2017
- Last registry update
- December 2020
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: Placebo Cream, Ruxolitinib Phosphate Cream, INCB018424
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.